Creating a world free of disease
We strive to make rare medical breakthroughs routine. Historically, creating medicines has relied on semi-empirical, artisanal processes defined by trial, error, and long feedback delays.
Using the power of AI, Xaira is working to eliminate the bottlenecks and constraints across the entire drug development continuum.
Milestones
Awards




We’ve built a team dedicated to reinventing how medicines are created

Nobel Laureate Board Members

Combined Years of AI and Drug Development Experience

Cumulative Drugs Approved

In Fundraising
Our Leadership
Board of Directors

Vik Bajaj
Co-CEO and Co-Founder, Prometheus

Carolyn R. Bertozzi
Nobel Laureate, Stanford Professor

Kaye Foster
Former SVP, Global Human Resources, Onyx

Alex Gorsky
Co-Founder and General Partner, ICONIQ Capital; Former Chairman & CEO, Johnson & Johnson

Scott Gottlieb
Partner, NEA; Former FDA Commissioner

Stephen Knight
President & Senior Managing Partner, F-Prime

Mathai Mammen
CEO, President and Chairman, Parabilis Medicines

Robert Nelsen
Founder, ARCH Venture Partners

Richard Scheller
Chairman of R&D, Bridgebio; Former EVP, Genentech and Lasker Award Laureate

Marc Tessier-Lavigne
Former Chief Scientific Officer, Genentech; President Emeritus, Stanford University

Bryan White
Co-Founder & Chief Investment Officer, Sahsen Ventures

Sean Parker
Founder & Chairman, Parker Institute for Cancer Immunotherapy (PICI)

Jim Tananbaum
Founder & CEO, Foresite Capital
Advisors
Anima Anandkumar
Mathai Mammen
Tim Behrens
David Baker
Diane Mathis
Richard Heyman, PhD
Regina Barzilay
Richard Scheller
Jeff Jonker
Carolyn R. Bertozzi
Sarah Teichmann
George Kadifa
Chris Garcia
Jonathan Weissman, Ph.D
Olivia Zetter
Rod MacKinnon
investors
We seek extraordinary scientists, engineers, and operators


















